{'fraction_non_alphanumeric': 0.009784735812133072, 'fraction_numerical': 0.0, 'mean_word_length': 5.564102564102564, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Overview of clinical experience with methylprednisolone aceponate

Methylprednisolone aceponate is a new potent topical corticosteroid. Chemically it is a corticoid diester that rapidly penetrates the skin. It is rapidly metabolised and then conjugated so that although potent, it does not appear to cause serious local or systemic side effects. Clinical trials indicate that once daily applications are sufficient to control most eczematous disorders and that it is suitable and effective in atopic dermatitis.